Objective The aim of this study was to investigate aortic stiffness and left ventricular (LV) systolic and diastolic function in patients with differentiated thyroid cancer (DTC) on thyroxine (L-T4) therapy and after L-T4 withdrawal to assess the cardiovascular impact of long-term subclinical hyperthyroidism and short-term overt hypothyroidism. Methods Twenty-four patients who had had total thyroidectomy and radioiodine ablation for differentiated thyroid cancer were studied on two occasions: on TSH suppressive L-T4 therapy (sTSH 0.24 ± 0.11 mU/L), and 4 weeks after L-T4 withdrawal (sTSH 89.82 ± 29.36 mU/L). Echocardiography was performed and thyroid function, serum thyroglobulin, lipid parameters, homocystine, C-reactive protein, fibrinogen and von Willebrand factor activity (vWF) were measured. Twenty-two healthy volunteers matched for age and sex served as euthyroid controls. Results Aortic stiffness was increased both in hypothyroidism (6.04 ± 2.88 cm 2 /dyn/10 3 , p \ 0.05) and subclinical hyperthyroidism (9.27 ± 4.81 cm 2 /dyn/10 3 , p \ 0.05) vs. controls (3.92 ± 1.84 cm 2 /dyn/10 3 ). Subclinical hyperthyroidism had a more marked effect (p \ 0.05). LV dimensions and ejection fractions were similar before and after L-T4 withdrawal. The E 0 /A 0 was higher in euthyroid controls (1.34 ± 1.02) as compared to both subclinical hyperthyroidism (1.0 ± 0.14, p \ 0.05) and overt hypothyroidism (1.13 ± 0.98, p \ 0.05). Change of aortic stiffness correlated with change of free-thyroxine (fT4), vWF and fibrinogen levels in a positive manner. Conclusion Long-term thyrotropin-suppression therapy has continuous adverse effects on the arterial wall. The degree of TSH suppression in patients with DTC should be kept at the possible minimum, based on individually determined potential benefits and risks of treatment, especially in patients with cardiovascular co-morbidities.
Introduction
Thyroid hormones have several profound effects on the cardiovascular system [1] [2] [3] . Some of these effects can be studied in patients with differentiated thyroid cancer (DTC), who have been treated with total thyroidectomy and radioiodine ablative therapy. These patients are kept lifelong on suppressive thyroxine (L-T4) therapy, which is interrupted on a yearly basis by short periods of hypothyroidism to detect thyroglobulin as a tumor marker.
Subclinical hyperthyroidism is associated with higher heart rate, frequent atrial premature beats, and increased prevalence of atrial fibrillation [4, 5] . Increased left ventricular mass (LVM) and diastolic dysfunction are also reported in subclinical hyperthyroidism [4, [6] [7] [8] [9] [10] . However, the association between exogenous subclinical hyperthyroidism and cardiovascular morbidity and mortality is controversial [11] .
Changes of the cardiovascular system are well characterized in long-standing hypothyroidism: bradycardia, prolongation and increased dispersion of the QT interval [12] , increased blood pressure, particularly diastolic [13] , increased peripheral vascular resistance with a reduced cardiac output [14, 15] , and left ventricular diastolic dysfunction [16] . Overt hypothyroidism is related to coronary artery disease because of atherogen lipid profile, hypertension, hyperhomocysteinemia, elevated C-reactive protein levels, coagulation factor abnormalities, and endothelial dysfunction [17] . In contrast, there are only limited data available on the effects of short-term hypothyroidism induced by LT4-withdrawal on cardiovascular disease [18] . During short-term hypothyroidism nighttime systolic, diastolic and mean blood pressures were increased, left ventricular diastolic function was impaired [10, 19] , ejection fraction during effort was reduced [20] and afterload increased [13] . Endothelial dysfunction in short-term hypothyroidism has also been reported [21, 22] .
One of the recently described tools for determining cardiovascular risk is arterial wall stiffness which is an independent predictor of cardiac events [23] via several mechanisms. Increased cardiac afterload, impaired coronary blood flow, direct atherogenic action or microvascular damage may be contributing factors [23, 24] . Arterial stiffness can be calculated from the aortic diameter and blood pressure measured simultaneously [25] or can be determined by pulse wave analysis [26] . Central arterial stiffness is reduced in untreated hyperthyroidism based on analysis of the central arterial pressure waveform [27] . On the other hand, Palmieri et al. [28] detected increased total arterial stiffness in overt hyperthyroidism using echocardiography. Antithyroid drug therapy significantly reduced the stiffness of the common carotid artery in patients with Graves' disease [29] . Overt and subclinical hypothyroid subjects have increased arterial stiffness and it is reversed by L-T4 replacement [15, 30] . Aortic stiffness has not been measured in subclinical hyperthyroidism.
The aim of this study was to investigate aortic stiffness and left ventricular systolic and diastolic functions in patients with DTC who are on TSH suppressive doses of L-T4, as well as after 4 weeks of L-T4 withdrawal to assess the cardiovascular impact of both long-term subclinical hyperthyroidism and iatrogenic short-term hypothyroidism.
Patients and methods

Patients
Twenty-four women (mean age 42.4 ± 8.07 years) who had had total or near-total thyroidectomy for DTC were included in the study. In 21/24 cases, 131 I ablation was also performed within 6 months. Three of the 24 patients declined the recommended 131 I treatment because they wanted to be pregnant within a year. On the basis of the ATA guidelines [31] , all patients were classified as ''high or intermediate risk'' of DTC recurrence, and hence they were on TSH suppressive therapy (TSH 0.24 ± 0.11 mU/ L) continuously for at least 26 weeks and were taking no other medications. 20 ± 12.6 months elapsed before the start of this study.
Their yearly follow-up included TSH-stimulated serum thyroglobulin (Tg) level, anti-Tg antibodies, neck ultrasonography and, if indicated, whole-body radioiodine scan. We performed TSH-stimulated Tg evaluation after L-T4 withdrawal and endogenous rise in TSH. The use of recombinant TSH (rhTSH) is covered only in the presence of severe cardiac co-morbidities by the national health insurance plan in Hungary; these patients were excluded from the study. The first Tg measurement was at least 6 months after RAI in parallel with anti-Tg antibody (refence range \1 IU/ml). Four of the 24 patients were Tg positive (Tg [2 lg/L); in these patients, whole-body scan (WBS) was performed. WBS was positive in 3 of them due to small thyroid remnant and RAI was repeated. One Tg positive, WBS negative patient was followed and consequent Tg measurements were negative. Another three patients were Tg negative and anti-Tg positive. Patients with known ischemic heart disease, stroke, cardiac failure, hypertension, diabetes mellitus, renal or liver failure, and other systemic or malignant diseases (other than previous thyroid cancer) were excluded from the study. Twenty-two healthy volunteers, matched for age, served as euthyroid controls (TSH: 1.64 ± 1.05 mU/L). The same criteria were used in control subject selection, except that they had no history of thyroid disease. They were not taking any drug known to influence thyroid and/or cardiac function. The protocol was approved by the Institutional Ethics Committee. All study subjects gave written informed consent.
Study protocol
Patients were studied on the day before L-T4 withdrawal (subclinical hyperthyroidism) and 4 weeks later, before readministration of L-T4 (hypothyroidism). Controls were evaluated only once. Blood samples were collected between 08.00 and 09.00 am after an overnight fast for determination of TSH, free thyroxine (fT4), free triiodothyronine (fT3), thyroglobulin, cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total homocystine (Hcys), C-reactive protein (CRP), fibrinogen and von Willebrand factor activity (vWF). Blood pressure was measured, body mass index (BMI) calculated (the individual's body mass divided by the square of their height) and echocardiography performed. Echocardiographic measurements were carried out by two independent investigators who were unaware of the patients' clinical data.
Aortic wall stiffness and left ventricular mass measurements
Transthoracic echocardiography was performed using Philips HDI-5000 system (Philips Medical Systems, Bothell, USA) 2.5 MHz probe at the left lateral decubitus position in a standard manner. M-mode tracings of the ascending aorta were obtained in the parasternal long axis views at a speed of 50 mm/s. Five consecutive cardiac cycles were averaged for every echocardiographic measurement. With M-mode, aortic tracing was recorded at the level of approximately 3 cm above the aortic valve. From the M-mode recordings, aortic systolic and diastolic diameters (Aos and Aod, respectively) were measured. Aos was determined at the time of the full opening of the aortic valve and Aod was determined at the peak of QRS. All parameters were measured in five consecutive cardiac cycles and averaged. Simultaneously, cuff brachial artery systolic (SBP) and diastolic (DBP) blood pressures were measured and recorded.
The aortic elasticity parameters, the aortic strain and aortic stiffness index were calculated using the following formulas [32] :
M-mode measurements of LV internal dimension in diastolic (LVDD) and systolic (LVDS), and end-diastolic posterior wall (PW) and interventricular septum (IVS) thickness and left atrium anteroposterior diameter were obtained using the standard technique. LV fractional shortening, a measure of the percent change in LV dimensions with systole, was calculated as
LV mass (LVM) was calculated using the formula:
LVM was corrected for body surface area to obtain LVM index (LVMI) [33] . Two-dimensional left ventricular ejection fraction (LVEF) was also acquired by the summation method. We used tissue Doppler imaging (TDI) to determine LV diastolic function.
The peak early transmitral filling velocity during early diastole (E), peak transmitral atrial filling velocity during late diastole (A), and E/A ratio were used as left ventricular diastolic function parameters. Quantitative diastolic data were derived from TDI data. The sample volume (4 mm 3 ) was placed in the LV basal portion of anterior, inferior, septal and lateral walls (using the 2-and 4-chamber images) The following parameters (mean values calculated from three consecutive beats) were derived: early diastolic velocity (E 0 ), late diastolic velocity (A 0 ) and the E 0 /A 0 ratio [34] . Parameters of the patient groups were compared to controls.
Biochemical measurements TSH, serum fT4 and fT 3 and thyroglobulin levels were measured by chemiluminescence immunoassay (DiaSorin, Saluggia). Total serum cholesterol, triglyceride, LDL-C and HDL-C were assayed by enzymatic methods (Roche Diagnostics, Mannheim, Germany). Hcys levels were measured by fluorescence polarisation immunoassay (Abbott Laboratories, Abbott Park, IL, USA). Fibrinogen was assayed by the Clauss method (Diagnostico Stago, Asnieres-sur-Seine, France). vWF and CRP were assayed by latex-sensitized immunoturbidimetry (Diagnostico Stago, Asnieres-sur-Seine, France, and Roche Diagnostics, Mannheim, Germany, respectively).
Reference ranges are as follows:
Statistical analysis
All statistical analyses were performed using the SAS for Windows (8.2 cary/nc SAS Ò Institute Inc. USA) statistical package. Continuous data were expressed as mean ± SD. Relationships between the continuous variables were evaluated by Pearson's or Spearman's correlation analysis. Comparisons between control, subclinical hyperthyroid and hypothyroid groups for continuous variable were made by one-way ANOVA and post hoc Tukey's test. To improve the normality of the data distribution, triglyceride values were log transformed for analysis. Simple linear regression analyses were performed to asses the relationship between changes of aortic stiffness and other parameters. To investigate the independent effect of the different factors on changes of stiffness, a multiple stepwise linear regression model was used. The multivariate model consisted of the changes of stiffness index as dependent variable and independent variables that had had significant correlation with changes of stiffness index in the simple linear regression analysis, i.e., vWF, fibrinogen, fT4 and LDL-C. p \ 0.05 was considered statistically significant.
Results
Clinical and laboratory parameters
In subclinical hyperthyroidism, the mean TSH level was 0.24 ± 0.11 mU/L while the fT3 and fT4 levels were within the normal range (4.79 ± 0.46 and 18.39 ± 2.33 pmol/L, respectively). After discontinuation of L-T4 for 4 weeks, all 24 subjects achieved a hypothyroid state, as evidenced by TSH levels (89.8 ± 29.36 mU/ L) and low serum fT4 and fT3. Blood pressure and BMI were not significantly different in hypothyroidism compared to subclinical hyperthyroidism and euthyroid state. Cholesterol, triglyceride, and LDL-C increased in hypothyroidism significantly compared to subclinical hyperthyroidism and were lower in subclinical hyperthyroidism than in hypothyroidism. Hcys was significantly higher in the hypothyroid state than in subclinical hyperthyroidism and was the lowest in euthyroid controls. Mean HDL-C levels were unchanged. Average CRP levels exceeded 1.0 mg/L in both hypothyroidism and subclinical hyperthyroidism (low cardiovascular risk: \1.0 mg/L). However, CRP values were significantly higher in subclinical hyperthyroidism. The fibrinogen and vWF values were higher in subclinical hyperthyroidism, although the mean value of vWF remained within the reference range. The results of the two different hormonal states were compared with data of the healthy euthyroid control group (Table 1) .
Aortic stiffness
Aortic stiffness increased significantly in both the hypo (p \ 0.05) and subclinical hyperthyroid (p \ 0.01) groups compared to controls. However, in hypothyroidism, values between the subclinical hyperthyroid and control groups were observed. The difference in aortic stiffness was also significant between subclinical hyperthyroidism and overt hypothyroidism (p \ 0.05) (Fig. 1) .
As far as LV dimension and ejection fraction are concerned, no significant changes were observed in M-mode measurements (LVEDD, LVESD, IVS, PW and fractional shortening) and in the two-dimensional study (LVM, LVMI and LVEF) either during L-T4 withdrawal, or when compared with healthy controls (Table 2) .
Diastolic function parameters, E-, A-, E 0 -waves were significantly lower in both subclinical hyperthyroidism and overt hypothyroidism compared to healthy controls. significantly lower in subclinical hyperthyroidism and in hypothyroidism than in controls, but this ratio was lower in subclinical hyperthyroidism than in hypothyroidism. The differences in E 0 /A 0 were significant. Heart rate was lower in hypothyroidism and higher in subclinical hyperthyroidism compared with controls (Table 3) .
Correlation between changes in aortic stiffness and laboratory parameters By simple regression analysis, changes of aortic stiffness index during transition from subclinical hyperthyroidism to hypothyroidism correlated with changes of vWF (r = 0.61, p = 0.013) (Fig. 2) , fT4 (r = 0.65, p = 0.01) (Fig. 3) and fibrinogen (r = 0.51, p = 0.01) (Fig. 4) in a positive manner, while with LDL-C in a negative manner (r = -0.49, p = 0.01).
Stepwise multiple regression analysis to evaluate association between aortic wall stiffness index and other parameters Table 4 presents the results of stepwise multiple regression analysis of changes in various clinical variables. In this model, which included aortic stiffness index, vWF, fibrinogen, fT4 and LDL-C, only vWF and fT4 emerged as independent factors associated with a positive manner with aortic stiffness (Table 4) .
Discussion
In the present study, we examined aortic stiffness as well as systolic and diastolic function in a cohort of patients in two subsequent measurements, first in subclinical hyperthyroidism while on L-T4 suppression therapy, and in overt hypothyroidism after L-T4 withdrawal. We found increased aortic stiffness and decreased diastolic function in both subclinical hyperthyroidism and overt hypothyroidism. These undesirable changes may represent lifelong cardiovascular risk in DTC patients. However, the effect of the 4 weeks L-T4 withdrawal was less marked on both aortic stiffness and diastolic function. We speculate that 4 weeks are not enough to develop the entire effect of hypothyroidism on peripheral tissue. As subclinical hyperthyroidism is sustained for decades in these patients, the undesirable changes caused by this condition are more important in DTC patients. To the best of our knowledge, this is the first study which examines aortic stiffness and systolic and diastolic heart function simultaneously in subclinical hyperthyroidism.
The cardiovascular risk factors cause structural and functional vascular damage. One of the non-invasive methods used to study this functional damage is arterial stiffness measurement. Aortic stiffness can be assessed by pulse wave velocity or by ultrasonically measured pulsatile aortic dimension changes [24, 32] . We used the latter technique to evaluate the cardiovascular risk.
The relationship between cardiovascular morbidity and mortality in iatrogenic subclinical hyperthyroidism is controversial [11] . Only few data are available on aortic stiffness in hyperthyroidism. Obuobie et al. [27] found lower central arterial stiffness in untreated thyrotoxic patients that may be cardioprotective. In another study, systemic arterial stiffness was found increased parallel with decreased subendocardial perfusion in hyperthyroidism [35] . In hypothyroidism, central arterial stiffness is increased [15] , and it improves after restoration of euthyroidism [30] . In our study, the aortic stiffness was significantly higher in long-term subclinical hyperthyroidism than in euthyroid controls and in short-term hypothyroidism. T4 was an independent factor associated with a positive manner with aortic stiffness. The mechanisms by which thyroid hormone excess affects vascular physiology are still unclear. Thyroid hormones have direct effects on the endothelium (endothelium-dependent vasodilatation) that is modulated by T3 and the effector is nitrogen-monoxide [36, 37] . It has been also shown that thyroid hormones cause rapid relaxation of vascular smooth muscle (endothelium-independent vasodilatation) [38] . Recently, we found better endothelial function while slightly impaired vascular injury markers and inflammatory status in subclinical hyperthyroidism [22] . We concluded that these apparently opposing mechanisms may compensate for each other at the level of the vessel wall. Therefore, better endothelial function and decreased arterial stiffness can be expected in subclinical hyperthyroidism. Regarding aortic stiffness, our findings are in sharp contradiction with this assumption. Sympathetic activation increases arterial wall stiffness [24] . Manifestations of hyperthyroidism resemble the effect of catecholamine excess: the sensitivity of resistance vessels to the vasoconstrictive action of norepinephrine is enhanced [39] . b1-adrenergic blockade was associated with normalization of total arterial stiffness [28] . Our previous report of low-grade inflammation in subclinical hyperthyroidism has been confirmed by a recent study [40] . Vascular inflammation causes degradation of collagen and elastin, evokes changes in the proteoglycan composition and hydration status, and results in medial calcification [41] leading to increased arterial stiffness. Low-grade inflammation caused endothelial dysfunction and impaired NO availability in patients with subclinical hypothyroidism [42] . Thyroid hormone reduces systemic vascular resistance and causes activation of the renin-angiotensinaldosterone system. T3 directly stimulates the synthesis of renin substrate in the liver. Consequent sodium reabsorption, increased blood volume and preload contribute to the characteristic increase in cardiac output [43] . Chronic hemodynamic overload causes increased myocardial contractility, cardiac hypertrophy, increased left ventricular mass; contractile protein synthesis is increased. The faster heart rate in hyperthyroidism results in an earlier return of the forward pressure wave in systole and in a greater overlapping in the forward and reflected pressure waves [28] . vWf is reported to be a reliable marker of endothelial damage and subclinical atherosclerosis [44] . In the present study, vWF and fibrinogen as markers of endothelial dysfunction were higher in subclinical hyperthyroidism than in overt hypothyroidism, and there was positive correlation between changes of aortic stiffness index, vWF and fibrinogen during transition from subclinical hyperthyroidism to hypothyroidism. These changes may be associated with relative hypercoagulability and increased thromboembolic risk [45] . Most previous studies used isovolumic relaxation time to evaluate diastolic dysfunction in subclinical hypo-and hyperthyroidism. Our results, albeit using another approach, are consonant with these studies Impaired diastolic function was detected in patients with subclinical hyperthyroidism [8, 9, [46] [47] [48] [49] . It has been suggested in earlier studies that diastolic dysfunction in subclinical hyperthyroidism resulted from increased LVM. However, no significant increases in LVM were found either by us or by other groups [8, 50] . Dörr et al. [51] showed that decreased serum TSH levels were not associated with an elevated risk of left ventricular hypertrophy, but overt hyperthyroidism is an independent risk factor for left ventricular hypertrophy. Thyroid hormones influence calcium regulation in myocytes, such as increased Ca??-ATPase activity, decreased phospholamban expression, and increased Ca-influx. [52] . Increase in intracellular calcium may be the cause of mediated diastolic stiffness in hyperthyroid rat hearts [53] .
We detected only slight impairment in aortic stiffness and diastolic function in acute short-term hypothyroidism. Aortic stiffness is likely related to myxedema of the arterial wall [15, 54] . However, our data do not support this notion and are consonant with the findings of other studies [15, 30, 55] that argued against the role of LDL-C in increased aortic stiffness. Impaired diastolic function in hypothyroidism due to slow myocardial relaxation results from altered intracellular calcium handling, decreased activity of the sarcoplasmatic reticulum calcium ATPase and/or increased expression of phospholamban [2] . Myofibril swelling and mucopolysaccharide accumulation can be detected in hypothyroid heart [52] .
In conclusion, our results confirm that both long-term TSH suppressive L-T4 therapy with the consequent subclinical hyperthyroidism and thyroxine withdrawal have several adverse effects on the heart and vessel wall. Impaired diastolic function and increased aortic stiffness may increase the cardiovascular risk. The degree of TSH suppression in patients with DTC should be kept at the possible minimum, considering the potential benefits and risks of treatment, especially in patients with cardiovascular co-morbidities, in agreement with the current international recommendations. Patients may benefit from the widespread use of rhTSH instead of thyroxine withdrawal to achieve high TSH during Tg measurement, as well as from beta-1 adrenergic blockade during iatrogenic subclinical hyperthyroidism.
